CLINICAL TRIALS PROFILE FOR ONGENTYS
✉ Email this page to a colleague
All Clinical Trials for ongentys
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02847442 ↗ | Efficacy and Safety of Opicapone in Clinical Practice | Completed | Bial - Portela C S.A. | Phase 4 | 2016-11-23 | The purpose of this study is to evaluate the change in subject's condition according to the Investigator's Global Assessment of Change after three months of treatment with 50 mg opicapone once daily in a heterogeneous patient population reflecting daily clinical practice. |
| NCT03116295 ↗ | Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone | Completed | Bial - Portela C S.A. | Phase 1 | 2017-06-20 | The purpose of this study is to evaluate the bioavailability and the bioequivalence between two active pharmaceutical ingredient (API) sources of opicapone (OPC) at two different dosage strengths (25 mg and 50 mg) after a single oral dose administration under fasting conditions in healthy male and female subjects. |
| NCT03820037 ↗ | Relative Bioavailability and Bioequivalence of Opicapone | Completed | Bial - Portela C S.A. | Phase 1 | 2019-03-19 | the purpose assess the relative bioavailability and bioequivalence of two active pharmaceutical ingredient (API) sources of opicapone (OPC, Ongentys® and BIA 9-1067) following single 50 mg dose administration under fasting conditions in healthy volunteers |
| NCT04265027 ↗ | Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OPC) | Completed | Bial - Portela C S.A. | Phase 1 | 2018-02-20 | This study evaluates the bioavailability and bioequivalence between two active pharmaceutical ingredient (API) sources of opicapone (OPC) at two different dosage strengths (50 mg and 25 mg) after single and multiple dose administration under fasting conditions in healthy volunteers and assess soluble catechol O methyltransferase (S-COMT) activity in 2 API sources of OPC at two different dosage strengths (50 mg and 25 mg) after single and multiple dose administration under fasting conditions in healthy volunteers |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ongentys
Condition Name
Clinical Trial Locations for ongentys
Clinical Trial Progress for ongentys
Clinical Trial Phase
Clinical Trial Sponsors for ongentys
Sponsor Name
